Aerie Pharmaceuticals reported $29.57M in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Aerie Pharmaceuticals AERI:US $ 29.57M 6.52M
Alimera Sciences ALIM:US $ 12.44M 2.22M
Amarin AMRN:US $ 58.63M 13.76M
Bluebird Bio BLUE:US $ -226000 6.14M
Endo International Ordinary Shares ENDP:US $ 472.5M 94.46M
Horizon Pharma HZNP:US $ 646.2M 23.99M
Insmed INSM:US $ 48.83M 7.91M
JAZZ PHA JAZZ:US $ 808.67M 110.23M
Merk MRK:US $ 10895M 328M
Novartis NOVN:VX 9.34B 277M
Pacira Pharmaceuticals PCRX:US $ 118.78M 3.13M
Regeneron Pharmaceuticals REGN:US $ 2560.1M 0.1M
Revance Therapeutics RVNC:US $ 17.37M 701K
Supernus Pharmaceuticals SUPN:US $ 149.59M 15.02M
Teva Pharmaceutical Industries TEVA:US $ 1828M 26M
Valeant Pharmaceuticals VRX:CN $ 1367M 203M
Zoetis ZTS:US $ 1432M 11M